NASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis $48.82 -0.07 (-0.14%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$48.25 -0.57 (-1.17%) As of 05/30/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About PTC Therapeutics Stock (NASDAQ:PTCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PTC Therapeutics alerts:Sign Up Key Stats Today's Range$48.02▼$49.0950-Day Range$36.19▼$55.3152-Week Range$28.72▼$58.38Volume790,857 shsAverage Volume860,058 shsMarket Capitalization$3.87 billionP/E RatioN/ADividend YieldN/APrice Target$63.75Consensus RatingModerate Buy Company OverviewPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More… PTC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScorePTCT MarketRank™: PTC Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 207th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingPTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoveragePTC Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PTC Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -8.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -8.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PTC Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.09% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 3.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.38 Percentage of Shares Shorted7.09% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 3.19%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment1.29 News SentimentPTC Therapeutics has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for PTC Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,469,137.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of PTC Therapeutics is held by insiders.Read more about PTC Therapeutics' insider trading history. Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Stock News HeadlinesPTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells $40,635.66 in StockMay 20, 2025 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $63.75 Average Target Price from BrokeragesMay 31 at 2:21 AM | americanbankingnews.com"Elon’s #1 AI Stock” SET TO SOARBecause Elon Musk's AI promises to be 100x more powerful. After all, ChatGPT just works online... While Elon's AI works in the real world.May 31, 2025 | Behind the Markets (Ad)PTC Therapeutics (NASDAQ:PTCT) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysMay 29 at 1:31 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 26, 2025 | prnewswire.comThose who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51%May 22, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 20, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 18, 2025 | globenewswire.comSee More Headlines PTCT Stock Analysis - Frequently Asked Questions How have PTCT shares performed this year? PTC Therapeutics' stock was trading at $45.14 at the beginning of 2025. Since then, PTCT shares have increased by 8.2% and is now trading at $48.82. View the best growth stocks for 2025 here. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Tuesday, May, 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $9.19. The business's quarterly revenue was down 9.6% compared to the same quarter last year. Read the conference call transcript. Who are PTC Therapeutics' major shareholders? PTC Therapeutics' top institutional shareholders include Vanguard Group Inc. (10.86%), Armistice Capital LLC (6.86%), Wellington Management Group LLP (6.84%) and Driehaus Capital Management LLC (1.91%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Neil Gregory Almstead, Eric Pauwels, Lee Scott Golden, Pierre Gravier, Christine Marie Utter, Emily Luisa Hill, Allan Steven Jacobson, Jerome B Zeldis, David P Southwell, Alethia Young, Stephanie Okey and Emma Reeve. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD). Company Calendar Last Earnings5/06/2025Today5/31/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTCT CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Stock Price Target$63.75 High Stock Price Target$112.00 Low Stock Price Target$40.00 Potential Upside/Downside+30.6%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$6.51 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$626.60 million Net Margins-50.32% Pretax Margin-47.24% Return on EquityN/A Return on Assets-16.44% Debt Debt-to-Equity RatioN/A Current Ratio2.10 Quick Ratio2.04 Sales & Book Value Annual Sales$1.77 billion Price / Sales2.18 Cash Flow$2.35 per share Price / Cash Flow20.80 Book Value($10.85) per share Price / Book-4.50Miscellaneous Outstanding Shares79,257,000Free Float72,883,000Market Cap$3.87 billion OptionableOptionable Beta0.52 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:PTCT) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.